Sage Therapeutics Q1 2023 Earnings Report

Sage Therapeutics EPS Results

• Actual EPS: -$2.46
• Consensus EPS: -$2.50
• Beat/Miss: Beat by +$0.04
• One Year Ago EPS: -$2.07

Sage Therapeutics Revenue Results

• Actual Revenue: $3.30 million
• Expected Revenue: $2.28 million
• Beat/Miss: Beat by +$1.02 million
• YoY Revenue Growth: +120.00%

Sage Therapeutics Announcement Details

• Quarter: Q1 2023
• Date: 5/2/2023
• Time: Before Market Opens

Sage Therapeutics (NASDAQ:SAGE), a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.